A step‑by‑step guide to the mergers and acquisitions lifecycle, from strategy and target screening through valuation, due diligence, signing, closing, and post‑merger integration.
Every deal moves through the seven stages, with three decision checkpoints where both sides agree whether to continue. Read from top to bottom: each stage describes what happens, the work involved, the deliverable that must be produced before advancing, and how long it typically takes. Timelines are indicative; real durations shift with deal size, financing requirements, and regulatory review.
1. Strategy & Deal Thesis - Phase: Prepare
Before selecting a target, define the acquisition thesis. Decide whether the deal serves growth, new capabilities, market entry, or operational synergies. Convert that rationale into concrete screening criteria, set a budget, and establish a disciplined walk-away price so emotions or competing bidders do not inflate the deal later. This stage produces the acquisition blueprint, the strategic document that guides every decision that follows.
Key Output: Acquisition blueprint
Indicative Time: 2-4 weeks (shorter for focused strategic pivots; longer if portfolio review spans multiple business units)
Checkpoint 1: LOI Signed. Both sides formally agree the deal is worth investigating at full cost before committing to deeper diligence and expense.
2. Target Screening & Approach - Phase: Prepare
Map the competitive landscape, build a long list, then narrow it to a credible short list through confidential outreach. A teaser document tests buyer interest without disclosing identity; once interest is confirmed, an NDA unlocks real financial and operational information. The stage ends when a shortlist exists and key targets have signed NDAs, opening the door to structured evaluation.
Key Output: Shortlist + signed NDA
Indicative Time: 4-8 weeks (market mapping can run faster in consolidated industries; slower in fragmented sectors with many potential targets)
3. Valuation & Indicative Offer - Phase: Value
Triangulate value using multiple methods: discounted cash flow projections, comparable public-company trading multiples, and precedent transaction analysis. Layer in a synergy case (cost savings, revenue uplift, or strategic premium) to justify a price above standalone value. Package the result into a non-binding letter of intent that frames price, deal structure (cash, shares, earn-out), and exclusivity, giving both sides a common framework without legal obligation.
Key Output: Signed letter of intent
Indicative Time: 2-4 weeks (complex capital structures or cross-border tax considerations may extend this)
Checkpoint 2: Signing. Legally binding purchase agreement executed; the deal is subject to regulatory approvals, financing conditions, and other closing prerequisites.
4. Due Diligence - Phase: Verify
This is the core risk-control stage. Dedicated workstreams covering financial, legal, tax, commercial, HR, and IT matters examine every claim in the data room. Management sessions, site visits, and red-flag reports either confirm the valuation assumptions or reveal gaps that require price adjustments, warranty terms, or renegotiation. The stage is complete only when findings are documented and the price is either confirmed or revised with mutual agreement.
Key Output: DD findings, price confirmed (or renegotiated)
Indicative Time: 4-8 weeks (larger targets or highly regulated industries often require the full 8 weeks or more)
5. Negotiation & Signing - Phase: Commit
Translate due-diligence findings into the definitive agreement. Lock in price and structure (cash, equity, earn-out mechanisms) and define warranties, indemnities, and closing conditions that allocate risk between buyer and seller. At the same time, secure committed debt and equity financing so capital is available at closing. Once signed, both parties are legally bound to complete the transaction subject only to the conditions listed in the agreement.
Key Output: Signed purchase agreement
Indicative Time: 4-6 weeks (parallel financing negotiations can extend this if debt markets are volatile)
6. Approvals & Closing - Phase: Complete
Satisfy every closing condition: file merger-control applications with regulators, secure license and contract transfers, complete third-party consent processes, and resolve any remaining prerequisites. Once all conditions are met, execute completion: funds transfer, ownership passes, and the transaction closes. The deal is now legally complete; delivering its value is the work of the next stage.
Key Output: Ownership transferred (legal closing)
Indicative Time: 4-12 weeks (regulatory reviews, especially in multi- jurisdiction deals, are the primary variable)
Checkpoint 3: Closing. The transaction is complete and ownership has changed hands; the remaining work is to realize the strategic value promised in the acquisition blueprint.
7. Post-Merger Integration - Phase: Deliver
Value is captured during integration, which is why this stage gets the most time. Combine people, systems, and processes against a Day-1 readiness plan that was developed before signing. A 100-day plan sets immediate priorities; longer-term synergy tracking links results back to the original deal thesis. Integration is continuous, typically six months to a year and a half, and requires the same discipline applied during the deal itself.
Key Output: Integrated business (operational and strategic value realized)
Indicative Time: 6-18 months (cultural integration and IT consolidation often extend timelines beyond initial estimates)
Three principles that keep deals on track:
- Prepare Early: A clean data room, realistic timetable, and clearly defined outputs prevent most mid-deal stalls and renegotiations.
- Stay Disciplined: Set the walk-away price before emotions and competitive dynamics inflate it; maintain the discipline established in the strategy stage.
- Integrate From Day One: Integration planning must begin before signing, not after closing; the Day-1 plan should be approved before the deal closes.
Durations are indicative. Actual timelines vary with deal size, financing complexity, and the scope of regulatory review required in the jurisdictions involved.
